Table 1. Baseline characteristics of study population and descriptive statistics.
| Characteristics | N (% or range) |
|---|---|
| Gender | |
| M | 87 (66.9) |
| F | 43 (33.1) |
| Median Age | 48.5 (18-81) |
| ECOG Performance Status | |
| 0-1 | 124 (95.4) |
| 2 | 6 (4.6) |
| Treatment | |
| ICT followed by CTRT | 101 (77.7) |
| CTRT | 29 (22.3) |
| Neck surgerya | |
| YES | 26 (20) |
| NO | 104 (80) |
| Stage (VII AJCC) | |
| II | 18 (13.8) |
| III | 40 (30.8) |
| IVa | 26 (20) |
| IVb | 46 (35.4) |
| Median EBV DNA | 554 (0-151075) |
| EBV DNAb | |
| UQ | 5 (3.8) |
| Neg | 27 (20.8) |
| Q | 50 (38.5) |
| Q+ | 48 (36.9) |
| Relapse | 28 (21.5) |
| Locoregional | 12 (42.9) |
| Distant | 16 (57.1) |
| Death | 18 (13.9) |
| Due to disease | 15 (83.3) |
| Due to other causes | 3 (16.7) |
ECOG: Eastern Cooperative Oncology Group.
AJCC: American Joint Committee on Cancer.
a Lymph node neck dissection or excisional biopsy.
b EBV DNA was stratified into 4 groups: Neg, Negative (EBV DNA = 0); UQ, Positive but UnQuantifiable (0 < EBV DNA < 102 copies/mL); Q, Positive and quantifiable (102 ≤ EBV DNA ≤ 15 × 102 copies/mL); Q+, Strongly positive and quantifiable (EBV DNA > 15 × 102 copies/mL).